Recent progress in vaccines against fungal diseases

Current Opinion in Microbiology

Volumn 15, Issue 4, 2012, Pages 427-433

  Cassone, Antonio ^a,b   Casadevall, Arturo ^a,b  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; FUNGUS VACCINE;

CANDIDIASIS; CHRONICITY; DRUG EFFICACY; DRUG FORMULATION; DRUG RESEARCH; DRUG TREATMENT FAILURE; HUMAN; IMMUNOGENICITY; INFECTION PREVENTION; MORBIDITY; MORTALITY; MYCOSIS; NONHUMAN; REVIEW;

ASPERGILLOSIS; CANDIDIASIS, VULVOVAGINAL; CRYPTOCOCCOSIS; FEMALE; FUNGAL VACCINES; FUNGI; HUMANS; MYCOSES;

FUNGI;

EID: 84865278725     PISSN: 13695274     EISSN: 18790364     Source Type: Journal    
DOI: 10.1016/j.mib.2012.04.004     Document Type: Review

References (52)

1. Cutler J.E., Deepe G.S., Klein D. Advances in combating fungal diseases: vaccines on the threshold. Nat Rev Microbiol 2007, 5:13-28.
2. Cassone A. Fungal vaccines: real progress from real challenge. Lancet Infect Dis 2008, 8:114-124.
3. Spellberg B. Vaccines for invasive fungal infections. F1000 Med Rep 2011, 3:13.
4. Stevens D.A., Clemons K.V., Liu M. Developing a vaccine against aspergillosis. Med Mycol 2010, 49(Suppl 1):S170-S176.
5. Datta K., Pirofski L.A. Towards a vaccine for Cryptococcus neoformans: principles and caveats. FEMS Yeast Res 2006, 6:525-536.
6. Rappuoli R., Mandl C.W., Black S., De Gregorio E. Vaccines for the twenty-first century society. Nat Rev Immunol 2011, 11:865-872.
7. Moxon E.R., Siegrist C.A. The next decade of vaccines: societal and scientific challenges. Lancet 2011, 378:348-359.
8. Fidel P.L., Cutler J.E. Prospects for development of a vaccine to prevent and control vaginal candidiasis. Curr Infect Dis Rep 2011, 13:102-1077.
9. Wang S.J. Candida vaccines development from point view of US patent application. Hum Vaccine 2011, 7:1165-1171. http://www.ncbi.nlm.nih.gov/pubmed/22048114.
10. + T cells: implications for vaccine development in immune-deficient hosts. J Exp Med 2003, 197:1405-1416.
11. Koh A.Y., Köhler J.R., Coggshall K.T., Van Rooijen N., Pier G.B. Mucosal damage and neutropenia are required for Candida albicans dissemination. PLoS Pathog 2008, 4:e35.
12. Bozza S., Perruccio K., Montagnoli C., Gaziano R., Bellocchio S., Burchielli E., Nkwanyuo G., Pitzurra L., Velardi A., Romani L. A dendritic cell vaccine against invasive aspergillosis in allogeneic hematopoietic transplantation. Blood 2003, 102:3807-3814.
13. Cardinale F., Chinellato I., Caimmi S., Peroni D.G., Franceschini F., Miraglia Del Giudice M., Bernardini R. Perioperative period: immunological modifications. Int J Immunopathol Pharmacol 2011, S3-S12.
14. Pfaller M.A., Diekema D.J. Epidemiology of invasive mycoses in North America. Crit Rev Microbiol 2010, 36:1-53.
15. Xin H., Cutler J.E. Vaccine and monoclonal antibody that enhance mouse resistance to candidiasis. Clin Vaccine Immunol 2011, 18:1656-1667.
16. Sandini S., La Valle R., Deaglio S., Malavasi F., Cassone A., De Bernardis F. A highly immunogenic recombinant and truncated protein of the secreted aspartic proteases family (rSap2t) of Candida albicans as a mucosal anticandidal vaccine. FEMS Immunol Med Microbiol 2011, 62:215-224.
17. Ostrowski-Zeichner L., Casadevall A., Galgiani J.N., Odds F.C., Rex J.H. An insight into the antifungal pipeline: selected new molecules and beyond. Nat Rev Drug Discov 2010.
18. Bromuro C., Romano M., Chiani P., Berti F., Tontini M., Proietti D., Mori E., Torosantucci A., Costantino P., Rappuoli R., Cassone A. Beta-glucan-CRM197 conjugates as candidates antifungal vaccines. Vaccine 2010, 28:2615-2623.
19. Xin H., Dziadek S., Bundle D.R., Cutler J.E. Synthetic glycopeptide vaccines combining beta-mannan and peptide epitopes induce protection against candidiasis. Proc Natl Acad Sci U S A 2008, 105:13526-13531.
20. Luo G., Ibrahim A.S., Spellberg B., Nobile C.J., Mitchell A.P., Fu Y. Candida albicans Hyr1p confers resistance to neutrophil killing and is a potential vaccine target. J Infect Dis 2010, 201:1718-1728.
21. Spellberg B.J., Ibrahim A.S., Avanesian V., Fu Y., Myers C., Phan Q.T., Filler S.G., Yeaman M.R., Edwards J.E. Efficacy of the anti-Candida rAls3p-N or rAls1p-N vaccines against disseminated and mucosal candidiasis. J Infect Dis 2006, 194:256-260.
22. Ito J.I., Lyons J.M., Hong T.B., Tamae D., Liu Y.K., Wilczynski S.P., Kalkum M. Vaccinations with recombinant variants of Aspergillus fumigatus allergen Asp f 3 protect mice against invasive aspergillosis. Infect Immun 2006, 74:5075-5084.
23. Datta K., Lees A., Pirofski L.A. Therapeutic efficacy of a conjugate vaccine containing a peptide mimotope of cryptococcal capsular polysaccharide glucuronoxylomannan. Clin Vaccine Immunol 2008, 15:1176-1187.
24. Saville S.P., Lazzell A.J., Chaturvedi A., Monteagudo C., Lopez-Ribot J.L. Efficacy of a genetically engineered Candida albicans tet-NRG1 strain as an experimental live attenuated vaccine against hemathogeneously disseminated candidiasis. Clin Vaccine Immunol 2009, 16:430-432.
25. Li W.Q., Hu X.C., Zhang X., Ge Y., Zhao S., Hu Y., Ashman R.S. Immunization with the glycolytic enolase confers effective protection against Candida albicans infection in mice. Vaccine 2011, 29:5526-5533.
26. Liu M., Capilla J., Johansen M.E., Alvarado D., Martinez M., Chen V., Clemons K.V., Stevens D.A. Saccharomyces as a vaccine against systemic aspergillosis: 'the friend of man' a friend again?. J Med Microbiol 2011, 60:1423-1432.
27. Cutler J.E., Corti M., Lambert P., Ferris M., Xin H. Horizontal transmission of Candida albicans and evidence for a vaccine response in mice colonized with the fungus. PLoS ONE 2011, 6.
28. Seubert A., Calabro S., Santini L., Galli B., Genovese A., Valentini S., Aprea S., Colaprico A., D'Oro U., Giuliani M.M., et al. Adjuvanticity of the oil-in-water emulsion MF59 is independent of Nlrp3 inflammasome but requires the adaptor protein MyD88. Proc Natl Acad Sci U S A 2011, 108:11169-11174.
29. Ferwerda G., Netea M.C., Joosten L.A., Van der Meer J.W.M., Romani L., Kullberg B.J. The role of Toll-like receptors and C-type lectins for vaccination against Candida albicans. Vaccine 2010, 28:614-622.
30. Chauban A., Swaleha Z., Ahmad N., Farazzudin M., Vasco A., Abida M., Mohammad O. Escheriosomes mediated cytosolic delivery of Candida albicans proteins induces enhanced cytotoxic T lymphocyte response and protective immunity. Vaccine 2011, 29:5424-5433.
31. De Bernardis F, Amacker M, Aranciaa S, Sandini S, Gremionb C, Moser C, Zurbriggen R, Cassonea A: A virosomal vaccine against candidal vaginitis: immunogenicity, efficacy and safety profile in animal models. Vaccine, in press.
32. Romani L. Immunity to fungal infections. Nat Rev Immunol 2011, 11:275-288.
33. Torosantucci A., Chiani P., Bromuro C., De Bernardis F., Palma A.S., Liu Y., Mignogna G., Maras B., Colone M., Stringaro A., et al. Protection by anti-beta-glucan antibodies is associated with restricted beta-1,3-glucan binding specificity and inhibition of fungal growth and adherence. PLoS ONE 2009, 4:e5392.
34. Rachini A., Pietrella D., Lupo P., Torosantucci A., Chiani P., Bromuro C., Proietti C., Bistoni F., Cassone A., Vecchiarelli A. An anti-beta-glucan monoclonal antibody inhibits growth and capsule formation of Cryptococcus neoformans in vitro and exerts therapeutic, anticryptococcal activity in vivo. Infect Immun 2007, 75:5085-5094.
35. McClelland E.E., Nicola A.M., Prados-Rosales R., Casadevall A. Ab binding alters gene expression in Cryptococcus neoformans and directly modulates fungal metabolism. J Clin Invest 2010, 120:1355-1361.
36. Wultrich M., Gern B., Hung C.Y., Ersland K., Rocco N., Pick-Jacobs J., Galles J., Filutowicz H., Warner T., Evans M., et al. vaccine-induced protection against 3 systemic mycoses endemic to North America requires Th17 in mice. J Clin Invest 2011, 121:554-568.
37. Hung C.Y., Gonzales A., Wuthrich M., Klein B.S., Cole G.T. Vaccine immunity to coccidiodomycosis occurs by early activation of three signal pathways of T helper cell responses (Th1, Th2 and Th17). Infect Immun 2011, 79:4511-4522.
38. Lin L., Ibrahim A.S., Xu X., Farber J.M., Avanesian V., Baquir B., Fu Y., French S.W., Edwards J.E., Spellberg B. Th1-Th17 cells mediate protective adaptive immunity against Staphylococcus aureus and Candida albicans infection in mice. PLoS Pathog 2009, 5:e1000703.
39. + T cells mediate the protective effect of the recombinant Asp f3-based anti-aspergillosis vaccine. Infect Immun 2011, 79:266.
40. Zelante T., De Luca A., Bonifazi P., Montagnoli C., Bozza S., Moretti S., Belladonna M.L., Vacca C., Conte C., Mosci P., et al. IL-23 and the Th17 pathway promote inflammation and impair antifungal immune resistance. Eur J Immunol 2007, 37:2695-2706.
41. Fenoglio D., Poggi A., Catellani S., Battaglia F., Ferrera A., Seti M., Murdaca G., Zocchi M.R. Vdelta1 T lymphocytes producing IFNg patients and IL-17 are expanded in HIV-infected and respond to Candida albicans. Blood 2009, 113:6611-6618.
42. Spellberg B., Ibrahim A.S., Lin L., Avanesian V., Fu Y., Lipke P., Otoo H., Ho T., Edwards J.E. Antibody titer threshold predicts anti-candidal vaccine efficacy even though the mechanism of protection is induction of cell-mediated immunity. J Infect Dis 2008, 197:957-971.
43. Lin L., Ibrahim A.S., Baquir B., Avanesian V., Fu Y., Spellberg B. Immunological surrogate marker of rAls3p-N vaccine-induced protection against Staphylococcus aureus. FEMS Immunol Med Microbiol 2009, 55:293-295.
44. Torosantucci A., Bromuro C., Chiani P., De Bernardis F., Berti F., Galli C., Norelli F., Bellucci C., Polonelli L., Costantino P., et al. A novel glyco-conjugate vaccine against fungal pathogens. J Exp Med 2005, 202:597-606.
45. Chiani P., Bromuro C., Cassone A., Torosantucci A. Anti-beta-glucan antibodies in healthy human subjects. Vaccine 2009, 27:2513-2519.
46. Auci F.Y., Li X., Tanji M., Kasper D.A. Mechanisms of glycoconjugate vaccine activation of the adaptive immune system and its implications for vaccine design. Nat Med 2011, 17:1602-1609.
47. Stuehler C., Khanna N., Bozza S., Zelante T., Moretti S., Kruhm M., Lurati S., Conrad B., Worschech E., Stevanović S., et al. Cross-protective TH1 immunity against Aspergillus fumigatus and Candida albicans. Blood 2011, 117:58815891.
48. Subramaniam K., Metzger B., Hanau L.H., Guh A., Rucker L., Badri S., Pirofski L.A. IgM(+) memory B cell expression predicts HIV-associated cryptococcosis status. J Infect Dis 2009, 200:244-251.
49. Bequin B., Lin L., Ibrahim A.S., Avanesian V., Tu A., Edwards J., Spellberg B. Immunological reactivity of blood from healthy humans to the rAls3p-N vaccine. J Infect Dis 2010, 201:475-479.
50. De Bernardis F., Arancia S., Morelli L., Hube B., Sanglard D., Schäfer W., Cassone A. Evidence that members of the secretory aspartyl proteinase gene family, in particular SAP2, are virulence factors for Candida vaginitis. J Infect Dis 1999, 179:201-208.
51. Pietrella D., Rachini A., Pines M., Pandey N., Mosci P., Bistoni F., d'Enfert C., Vecchiarelli A. Th17 cells and IL-17 in protective immunity to vaginal candidiasis. PLoS ONE 2011, 6:e22770.
52. Stevens D.A. Vaccinate against aspergillosis! A call to arms of the immune system. Clin Infect Dis 2004, 38:1131-1136.